Surgical treatment for pulmonary metastases from esophageal carcinoma after definitive chemoradiotherapy: Experience from a single institution

Journal of Cardiothoracic Surgery

Haruhiko Kondo³  Hirofumi Yasui¹  Hirofumi Ogawa²  Yasuhiro Tsubosa⁴  Hiroshi Sato⁴  Yoshiki Kozu³ 

[1] Division of Gastrointestinal Medicine, Shizuoka Cancer Center, Shizuoka, Japan;Division of Therapeutic Radiology, Shizuoka Cancer Center, Shizuoka, Japan;Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka, Japan;Division of Esophageal Surgery, Shizuoka Cancer Center, Shizuoka, Japan

关键词: surgical treatment;    pulmonary metastases;    complete response;    definitive chemoradiotherapy;    esophageal carcinoma;   

Others  :  1153740
DOI  :  10.1186/1749-8090-6-135

 received in 2011-05-28, accepted in 2011-10-12,  发布年份 2011

【 摘 要 】

Background

Surgical treatment for pulmonary metastases is known to be a safe and potentially curative procedure for various primary malignancies. However, there are few reports regarding the prognostic role of surgical treatment for pulmonary metastases from esophageal carcinoma, especially after definitive chemoradiotherapy (CRT).

Methods

We retrospectively reviewed 5 patients who underwent surgical treatment for pulmonary metastases from esophageal carcinoma at our institution. The primary treatment for esophageal carcinoma was definitive CRT, and a complete response (CR) was achieved in all patients.

Results

The surgical procedure for pulmonary metastases was wedge resection, and pathological complete resection was achieved in all 5 patients. The disease free interval after definitive CRT varied from 7 to 36 months, with a median of 19 months. There were no perioperative complications, but postoperative respiratory failure occurred in 1 patient. The postoperative hospital stay varied from 4 to 7 days, with a median of 6 days. Three patients are now alive with a good performance status (PS) and are disease free. The other 2 patients died of primary disease. The overall survival after surgical treatment varied from 20 to 90 months, with a median of 29 months.

Conclusions

Surgical treatment should be considered for patients with pulmonary metastases from esophageal carcinoma who previously received CRT and achieved a CR, because it provides not only a longer survival, but also a good postoperative PS for some patients.

【 授权许可】

   
2011 Kozu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T: Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006, 82:254-260.
• [2]Lin BR, Chang TC, Lee YC, Lee PH, Chang KJ, Liang JT: Pulmonary resection for colorectal cancer metastases: duration between cancer onset and lung metastasis as an important prognostic factor. Ann Surg Oncol 2009, 16:1026-1032.
• [3]Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura H, Tsuchiya R, Naruke T: Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996, 112:867-874.
• [4]Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Medioni J, Rougier P: Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg 89:375-380.
• [5]Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, Gohl J, Hohenberger W: Surgical management of pulmonary metastases from colorectal cancer in 153 patients. Ann Surg Oncol 2006, 13:1538-1544.
• [6]Chen F, Sato K, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg 2008, 7:809-812.
• [7]Shiono S, Kawamura M, Sato T, Nakagawa K, Nakajima J, Yoshino I, Ikeda N, Horio H, Akiyama H, Kobayashi K: Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol 2008, 3:1046-1049.
• [8]Jiao X, Krasna MJ: Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002, 74:278-284.
• [9]Ozawa S, Tachimori Y, Baba H, Matsubara H, Muro K: Comprehensive registry of esophageal cancer in Japan, 2002. Esophagus 2010, 7:7-22.
• [10]Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003, 21:2697-2702.
• [11]Chan A, Wong A: Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys 1999, 45:265-270.
• [12]Hironaka S, Ohtsu A, Boku N, Muto M, Nagashima F, Saito H, Yoshida S, Nishimura M, Haruno M, Ishikura S, Ogino T, Yamamoto S, Ochiai A: Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 2003, 57:425-433.
• [13]Nakamura T, Hayashi K, Ota M, Eguchi R, Ide H, Takasaki K, Mitsuhashi N: Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg 2004, 188:261-266.
• [14]Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL: Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002, 123:175-183.
• [15]Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases J Thorac Cardiovasc Surg 1997, 113:37-49.
• [16]Monteiro A, Arce N, Bernardo J, Eugenio L, Antunes MJ: Surgical resection of lung metastases from epithelial tumors. Ann Thorac Surg 2004, 77:431-437.
• [17]Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, Vokes EE: Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005, 16:1320-1325.
• [18]Levard H, Pouliquen X, Hay JM, Fingerhut A, Langlois-Zantain O, Huguier M, Lozach P, Testart J: 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg 1998, 164:849-857.